市場調查報告書
商品編碼
1372553
藥品合約銷售組織市場規模和預測、全球和地區佔有率、趨勢和成長機會分析報告範圍:按服務、模組、治療領域、最終用戶和地理位置Pharmaceutical Contract Sales Organizations Market Size and Forecasts, Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Services, Modules, Therapeutic Area, End User, and Geography |
藥品合約銷售機構市場規模預計將從2022年的82.12億美元成長到2030年的158.20億美元;預計2022年至2030年年複合成長率為8.6%。
藥品合約銷售組織市場的成長歸因於數位技術的日益融合以及製藥公司對增加產品銷售的興趣日益濃厚。
遠距醫療和遠距詳細資訊的日益普及為藥品合約銷售組織 (CSO) 市場帶來了新的機會。數位健康科技的變革性影響重新定義了醫病互動,並徹底改變了藥品銷售的動態。遠距醫療具有促進虛擬諮詢和參與的能力,為公民社會組織的適應和創新創造了肥沃的土壤。遠端詳細資訊涉及使用數位管道傳達產品資訊並吸引醫療保健專業人員,成為公民社會組織擴大影響範圍的策略途徑。這項策略變化凸顯了製藥業為應對市場複雜性所採取的積極主動的方法。透過與公民社會組織合作,這些企業可以接觸到專業銷售人員,利用外部專業知識來提高市場滲透率並提高銷售效率。透過這種協作模式,製藥公司可以簡化其營運並專注於研發等關鍵能力,同時利用公民社會組織的特定知識來提高其產品的適銷性。製藥公司和民間社會組織之間不斷加強的合作表明了對適應的奉獻精神以及對競爭激烈的製藥行業發展動態的深刻把握。它也顯示了對資源最佳化的細緻入微的理解。這種互惠互利的合作關係使收入最大化成為可能,並從戰略上將製藥公司置於適應性和針對性強的市場策略對於長期成功至關重要的市場中。
基於最終用戶的見解
根據最終用戶,藥品合約銷售組織市場分為生物製藥公司和製藥公司。到 2022 年,製藥公司細分市場將佔據更大的市場佔有率。製藥公司是合約銷售組織 (CSO) 的主要最終用戶。這些公司利用公民社會組織作為策略合作夥伴,以加強其銷售和行銷工作、簡化市場准入並最佳化資源配置。
由於全球新小分子藥物上市數量不斷增加、大量製藥公司提供類似產品以及公司大量採用新技術進行合約銷售,製藥公司擴大轉向 CSO 服務。此外,為製藥公司招募和留住高效的銷售專業人員也具有挑戰性;這支持了製藥公司對 CSO 服務的需求。製藥公司擴大尋求公民社會組織幫助他們快速建立強大的銷售團隊,降低銷售團隊的管理成本,節省招募過程中的時間和精力,並發展兼職合約銷售團隊以消除投資需求。因此,製藥公司越來越注重節省金錢和時間,這增加了藥品合約銷售組織市場的銷售機會。
然而,預計生物製藥公司細分市場在 2022 年至 2030 年期間將實現更高的年複合成長率。生物製藥公司策略性地聘用公民社會組織來最佳化其營運的各個方面。這些合作關係有助於促進生物製藥公司的銷售和行銷活動。 CSO 提供一群經驗豐富的生物製藥產品銷售代表,從而實現全面的產品推廣和市場滲透。它們還可以根據需要靈活地擴展銷售工作,而無需內部團隊的長期財務承諾。此類合作為生物製藥公司提供專業知識、可擴展性和成本效率,使他們能夠專注於創新和研究,同時利用公民社會組織為成功產品商業化提供的專業技能和資源。
生物製藥公司正致力於提高其研究能力。根據製藥研發年度回顧,2022年,在研藥物總數中超過45%是生物製藥。由於生物製藥公司對研究和促進生物製藥和小分子藥物銷售的高度興趣,預計這些公司將把銷售活動外包給公民社會組織,以專注於他們的研究能力,這反過來又有望支持該細分市場的市場成長。
歐洲是市場第二大主導地區。隨著慢性病盛行率的快速上升、老年人口的不斷增加,以及各種治療應用對新藥物分子的需求不斷增加,以滿足未滿足的需求,該地區對藥品的需求正在顯著成長。近 550 家製藥公司在德國開展業務。該國的合約銷售組織(CSO)為大型製藥公司和小型生物技術公司提供服務,幫助他們在歐洲市場取得領先地位。根據德國貿易投資總署的資料,2020年德國藥品銷售額較2019年成長6.7%,達607.9億美元(495億歐元)。
比利時的主要製藥公司包括楊森製藥、索爾維、UCB (Union Chimique Belge) 和 GMED Healthcare,以及巴斯夫安特衛普和葛蘭素史克生物製品等子公司。此外,大多數領先的跨國公司——包括輝瑞、賽諾菲-安萬特、諾華、葛蘭素史克和阿斯特捷利康——在西班牙都有直接業務。這些製藥巨頭的存在增強了歐洲製藥市場的實力。市場參與者採取的銷售成長策略預計將推動該地區的藥品合約銷售組織市場。 CSO 幫助新興製藥公司實現品牌成功並確保財務生存能力。他們在市場分析和目標分析等領域的專業知識幫助製藥公司超越目標。公民社會組織利用資料分析工具收集市場洞察、追蹤產品績效並發現機會。這種數據驅動的方法可以實現更有針對性的行銷和銷售工作。他們使用機器學習和人工智慧演算法來分析資料、預測銷售趨勢並個人化行銷內容。因此,由於頂級製藥公司的存在、製藥公司與公民社會組織的合作以及市場參與者擴大影響力的戰略努力,製藥和生物製藥行業的激增推動了歐洲藥品合約銷售組織市場的成長。
德國貿易投資總署、GLOBOCAN、疾病管制與預防中心 (CDC) 和世界衛生組織 (WHO) 是在準備藥品合約銷售組織市場報告時參考的主要和次要來源。
註 - 將為以下提到的地區/國家提供類似的分析
注意 - 將為以下公司列表提供類似資訊
The pharmaceutical contract sales organizations market size is expected to grow from US$ 8.212 billion in 2022 to US$ 15.820 billion by 2030; it is estimated to record a CAGR of 8.6% during 2022 to 2030.
The pharmaceutical contract sales organizations market growth is attributed to the increasing integration of digital technologies and the growing interest of pharmaceutical companies to increase sales of products.
The increasing use of telemedicine and remote detailing leads to new opportunities for the pharmaceutical contract sales organizations (CSO) market. The transformative influence of digital health technologies has redefined patient-doctor interactions and revolutionized the dynamics of pharmaceutical sales. With its capacity to facilitate virtual consultations and engagements, telemedicine creates a fertile ground for CSOs to adapt and innovate. Remote detailing, which involves using digital channels to communicate product information and engage healthcare professionals, becomes a strategic avenue for CSOs to extend their reach. This strategic change highlights the pharmaceutical industry's proactive approach to navigating the market's complexity. By working with CSOs, these businesses can access specialist sales personnel, leveraging outside expertise to increase market penetration and improve sales effectiveness. Through this collaborative model, pharmaceutical companies may streamline their operations and concentrate on key capabilities like research and development while utilizing the specific knowledge of CSOs to increase the marketability of their products. The rising cooperation between pharmaceutical corporations and CSOs demonstrates a dedication to adaptation and a profound grasp of the developing dynamics within the very competitive pharmaceutical industry. It also displays a nuanced understanding of resource optimization. This mutually beneficial partnership makes revenue maximization possible and strategically places pharmaceutical firms in a market where adaptability and focused market strategies are essential for long-term success.
End User-Based Insights
Based on end user, the pharmaceutical contract sales organizations market is segmented into biopharmaceutical companies and pharmaceutical companies. The pharmaceutical companies segment held a larger market share in 2022. Pharmaceutical companies are the major end users of contract sales organizations (CSOs). These companies utilize CSOs as strategic partners to bolster their sales and marketing endeavors, streamline market access, and optimize resource allocation.
Pharmaceutical companies are increasingly turning to CSO services due to the growing number of new small molecule drug launches worldwide, the presence of a significant number of pharmaceutical companies offering similar products, and the high adoption of new technologies for contract sales by companies. Moreover, recruiting and retaining efficient sales professionals for pharmaceutical companies is challenging; this supports the demand for CSO services for pharmaceutical companies. Pharmaceutical companies are increasingly looking to CSOs to help them build strong sales teams quickly, reduce sales team overhead costs, save time and effort on the recruitment process, and develop part-time contract sales teams to eliminate the need for investments. Thus, the growing focus of pharmaceutical companies on saving money and time is boosting sales opportunities for the pharmaceutical contract sales organizations market.
However, the biopharmaceutical companies segment is anticipated to register a higher CAGR during 2022-2030. Biopharmaceutical companies strategically employ CSOs to optimize various facets of their operations. These partnerships are instrumental in bolstering the sales and marketing activities of biopharmaceutical companies. CSOs provide a roster of experienced sales representatives specializing in biopharmaceutical products, enabling comprehensive product promotion and market penetration. They also provide the agility to scale sales efforts as needed without the long-term financial commitment of an in-house team. Such collaborations offer biopharmaceutical companies expertise, scalability, and cost efficiencies, allowing them to focus on innovation and research while leveraging the specialized skills and resources that CSOs provide for successful product commercialization.
Biopharmaceutical companies are focusing on improving their research capabilities. According to the Pharma R&D annual review, in 2022, more than 45% of the total drugs in the pipeline were biopharmaceuticals. Owing to the high interest of biopharmaceutical companies in research and boosting the sales of biopharmaceutical and small molecule drugs, it is expected that these companies will outsource their sales activities to CSOs in order to focus on their research capabilities, which in turn is anticipated to support the market growth for the segment.
Europe is the second leading region in the market. The demand for pharmaceutical products is growing significantly in this region with the burgeoning prevalence of chronic diseases, the rising geriatric population, and increasing demand for new drug molecules for various therapeutic applications to fulfill unmet needs. Nearly 550 pharmaceutical companies have operations in Germany. Contract sales organizations (CSOs) in this country provide their services to large pharmaceutical companies and small-scale biotech companies, assisting them in attaining leading positions in the European market. As per data by Germany Trade & Invest, pharmaceutical sales in Germany increased by 6.7% in 2020 compared to 2019, reaching US$ 60.79 billion (EUR 49.5 billion).
Major pharmaceutical companies in Belgium include Janssen Pharmaceutica, Solvay, UCB (Union Chimique Belge), and GMED Healthcare, as well as subsidiaries such as BASF Antwerpen and GlaxoSmithKline Biologicals. Further, most leading multinationals-including Pfizer, Sanofi-Aventis, Novartis, GlaxoSmithKline, and AstraZeneca-have a direct presence in Spain. The presence of such pharmaceutical giants has strengthened the European pharmaceutical market. Sales growth strategies adopted by market players are anticipated to drive the pharmaceutical contract sales organizations market in the region. CSO helps attain brand success and secure the financial viability of an emerging pharmaceutical company. Their expertise in areas such as market analysis and targeting analysis helps pharmaceutical companies surpass their target goals. CSOs leverage data analytics tools to gather market insights, track product performance, and identify opportunities. This data-driven approach allows for more targeted marketing and sales efforts. They use machine learning and AI algorithms to analyze data, predict sales trends, and personalize marketing content. Therefore, the proliferating pharmaceutical and biopharmaceutical industries, owing to the presence of top pharmaceutical companies, collaborations of pharmaceutical companies with CSOs, and the strategic efforts of market players to enhance their reach, fuel the growth of the pharmaceutical contract sales organizations market in Europe.
Germany Trade & Invest, GLOBOCAN, the Centers for Disease Control and Prevention (CDC), and the World Health Organization (WHO) are among the primary and secondary sources referred to while preparing the pharmaceutical contract sales organizations market report.
Note - Similar analysis would be provided for below mentioned regions/countries
Note - Similar information would be provided for below list of companies